MedTrace Logo

LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris

NCT02888236 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2017-08-28

No results posted yet for this study

Summary

A study of LEO 32731 in the treatment of psoriasis vulgaris

Conditions

  • Psoriasis Vulgaris

Interventions

DRUG

LEO 32731

DRUG

LEO 32731 Placebo

Sponsors & Collaborators

  • LEO Pharma

    lead INDUSTRY

Principal Investigators

  • Sandra Philipp, PhD · Charite University, Berlin, Germany

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2017-06-20
Completion
2017-07-06

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02888236 on ClinicalTrials.gov